UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

NOTICE OF EFFECTIVENESS

Effective Date:November 17,
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Viridian Therapeutics Charts.
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Viridian Therapeutics Charts.

News Viridian Therapeutics, Inc.\\de

Form 8-K - Current report
Montag 15 Juli 2024 (1 Tag vor) • Edgar (US Regulatory)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mittwoch 3 Juli 2024 (2 Wochen vor) • Business Wire
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
Dienstag 11 Juni 2024 (1 Monat vor) • Business Wire
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Montag 10 Juni 2024 (1 Monat vor) • Edgar (US Regulatory)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Donnerstag 6 Juni 2024 (1 Monat vor) • Business Wire
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
Freitag 31 Mai 2024 (2 Monate vor) • Business Wire
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
Freitag 10 Mai 2024 (2 Monate vor) • Business Wire
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 8 Mai 2024 (2 Monate vor) • Edgar (US Regulatory)
Form 8-K - Current report
Mittwoch 8 Mai 2024 (2 Monate vor) • Edgar (US Regulatory)
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
Mittwoch 8 Mai 2024 (2 Monate vor) • Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Freitag 3 Mai 2024 (2 Monate vor) • Business Wire
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
Montag 29 April 2024 (3 Monate vor) • Business Wire

Weitere Viridian Therapeutics, Inc.\\de News-Artikel